CARDIOLOGY IN THE YOUNG, vol.28, no.4, pp.542-547, 2018 (Journal Indexed in SCI)
Article / Article
Title of Journal :
CARDIOLOGY IN THE YOUNG
Background Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study.